Medpace Holdings Inc vs PayPal Holdings, Inc. — how do they compare? Medpace Holdings Inc trades at $609.54 (market cap $16.81B), while PayPal Holdings, Inc. trades at $58.08 (market cap $50.53B). The key difference: PayPal Holdings, Inc. is far larger — about 3× Medpace Holdings Inc's market cap, and PayPal Holdings, Inc. pays a 0.95% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PYPL | |
|---|---|---|
Market Cap | $16.81B | $50.53B |
Sector | Technology | Financials |
52-Week High | $620.59 | $76.13 |
52-Week Low | $393.42 | $39.08 |
Enterprise Value | $16.43B | $52.68B |
Dividend Yield | — | 0.95% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.
Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.
PayPal (PYPL) trades at $59.07, down 1.19% on the day, with a bullish technical outlook supported by moving averages and strong cash flow. Recent earnings beat expectations, with Q2 2026 EPS of $1.38 exceeding the $1.28 consensus, while revenue grew 4.8% year-over-year. The company raised full-year 2026 guidance, signaling confidence in its turnaround under new leadership, amid acquisition interest from Stripe and Advent International at a $53 billion valuation rejected by the board.
PYPL presents a value opportunity with a low P/E of 11.17 and robust free cash flow, but faces risks from competitive pressures and economic sensitivity. Analyst consensus is mixed with 35.7% buy ratings, though institutional buying and undervaluation narratives support upside potential if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →